These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16909049)

  • 21. List of drugs in development for neurodegenerative diseases. Update June 2008.
    Pogacić V; Herrling P
    Neurodegener Dis; 2009; 6(1-2):37-86. PubMed ID: 18679022
    [No Abstract]   [Full Text] [Related]  

  • 22. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.
    Geldenhuys WJ; Van der Schyf CJ
    Expert Opin Drug Discov; 2013 Feb; 8(2):115-29. PubMed ID: 23231597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Turning down, but not off.
    Lipton SA
    Nature; 2004 Apr; 428(6982):473. PubMed ID: 15057811
    [No Abstract]   [Full Text] [Related]  

  • 24. An overview of the pathophysiology of neurodegenerative disorders.
    Willner C
    Altern Ther Health Med; 2004; 10(4):26-34; quiz 35, 96. PubMed ID: 15285272
    [No Abstract]   [Full Text] [Related]  

  • 25. Natural polyphenols against neurodegenerative disorders: potentials and pitfalls.
    Ebrahimi A; Schluesener H
    Ageing Res Rev; 2012 Apr; 11(2):329-45. PubMed ID: 22336470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.
    Wang Q; Yan J; Chen X; Li J; Yang Y; Weng J; Deng C; Yenari MA
    Exp Neurol; 2011 Jul; 230(1):27-34. PubMed ID: 20406638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacotherapy for degenerative dementias].
    Maloteaux JM
    Bull Mem Acad R Med Belg; 2005; 160(1-2):109-17; discussion 118-22. PubMed ID: 16116815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
    Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
    Morimoto B
    IDrugs; 2009 Jun; 12(6):349-52. PubMed ID: 19517313
    [No Abstract]   [Full Text] [Related]  

  • 30. Editorial: "Phytochemicals for Human Diseases: An Update".
    Nabavi SM; Daglia M
    Curr Drug Targets; 2017; 18(13):1467. PubMed ID: 29070008
    [No Abstract]   [Full Text] [Related]  

  • 31. Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases.
    Pallàs M; Verdaguer E; Jordà EG; Jiménez A; Canudas AM; Camins A
    Med Hypotheses; 2005; 64(1):120-3. PubMed ID: 15533627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
    Popovic N; Brundin P
    Int J Pharm; 2006 May; 314(2):120-6. PubMed ID: 16529886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Is good old minocycline a new neuroprotective drug?].
    Melero-Fernández de Mera RM; García-Martínez E; Fernández-Gómez FJ; Hernández-Guijo JM; Aguirre N; Galindo MF; Jordán J
    Rev Neurol; 2008 Jul 1-15; 47(1):31-8. PubMed ID: 18592478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neuroprotective approaches in neurology - dashed hopes?].
    Zipp F
    Drug Res (Stuttg); 2013 Nov; 63 Suppl 1():S12-3. PubMed ID: 24242029
    [No Abstract]   [Full Text] [Related]  

  • 35. The role of the blood brain barrier in neurodegenerative disorders and their treatment.
    Palmer AM
    J Alzheimers Dis; 2011; 24(4):643-56. PubMed ID: 21460432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration.
    Skaper SD; Walsh FS
    Mol Cell Neurosci; 1998 Nov; 12(4-5):179-93. PubMed ID: 9828084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection.
    Stone TW; Forrest CM; Darlington LG
    FEBS J; 2012 Apr; 279(8):1386-97. PubMed ID: 22248239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases.
    Porzner M; Müller T; Seufferlein T
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1765-72. PubMed ID: 19814656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Caspases and neuroprotection.
    Bilsland J; Harper S
    Curr Opin Investig Drugs; 2002 Dec; 3(12):1745-52. PubMed ID: 12528311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorinated molecules in the diagnosis and treatment of neurodegenerative diseases.
    Gaye B; Adejare A
    Future Med Chem; 2009 Aug; 1(5):821-33. PubMed ID: 21426082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.